Quaker Chemical appoints Neil Daniels as Chief Accounting Officer

Quaker Chemical Corporation (KWR) appointed Neil Daniels as Vice President, Chief Accounting Officer, effective upon his anticipated employment start date of November 16, 2026. The announcement was made on October 16, 2026, and Daniels will serve as the company's principal accounting officer in that role.

In connection with the appointment, Thomas Coler will cease to serve as the company's principal accounting officer, a position he has held since July 22, 2026. Coler will continue to serve as Executive Vice President and Chief Financial Officer.

The company entered into an Employment Agreement with Daniels on October 16, 2026. The agreement provides for an annual base salary of $370,000. Daniels is also eligible to participate in the company's Annual Incentive Plan, with a target award percentage of 35% of his base salary for 2027, contingent on the company's financial results and other objectives. Additionally, he is eligible for the Long-Term Performance Incentive Plan, which includes an annual grant of time-based restricted stock units and target performance stock units with an aggregate value of $110,000. The agreement includes a cash sign-on bonus of $175,000, which is subject to repayment under certain circumstances if Daniels terminates his employment.

Daniels brings extensive experience in financial leadership roles. He previously worked as a consultant to Teleflex Inc., having rejoined that organization in February 2025 after previously serving as Vice President of Finance and Assistant Corporate Controller for over ten years from 2012 through 2022. Prior to his return to Teleflex, Daniels served as Vice President and Global Controller at Nouryon from May 2024 to February 2025. Before that role, he was Vice President and Corporate Controller at Emergent BioSolutions from November 2022 through May 2024. Daniels is a Certified Public Accountant and holds a Bachelor of Business Administration in Accounting.

The Employment Agreement subjects Daniels to non-disclosure, non-competition, and non-solicitation covenants similar to those applicable to other company officers. He will also be entitled to medical, dental, and other benefits generally available to full-time U.S. employees. The company stated that there are no arrangements or understandings between Daniels and any other person regarding his selection, no family relationships between him and any director or executive officer, and no direct or indirect material interest in any existing or proposed transaction requiring disclosure under Item 404(a) of Regulation S-K. The full text of the Employment Agreement was filed as an exhibit to the Form 8-K Current Report.